Your browser doesn't support javascript.
loading
Designing clinical trials for patients who are not average.
Yankeelov, Thomas E; Hormuth, David A; Lima, Ernesto A B F; Lorenzo, Guillermo; Wu, Chengyue; Okereke, Lois C; Rauch, Gaiane M; Venkatesan, Aradhana M; Chung, Caroline.
Afiliação
  • Yankeelov TE; Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX 78712, USA.
  • Hormuth DA; Department of Diagnostic Medicine, The University of Texas at Austin, Austin, TX 78712, USA.
  • Lima EABF; Department of Oncology, The University of Texas at Austin, Austin, TX 78712, USA.
  • Lorenzo G; Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX 78712, USA.
  • Wu C; Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX 78712, USA.
  • Okereke LC; Division of Diagnostic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
  • Rauch GM; Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX 78712, USA.
  • Venkatesan AM; Livestrong Cancer Institutes, The University of Texas at Austin, Austin, TX 78712, USA.
  • Chung C; Oden Institute for Computational Engineering and Sciences, The University of Texas at Austin, Austin, TX 78712, USA.
iScience ; 27(1): 108589, 2024 Jan 19.
Article em En | MEDLINE | ID: mdl-38169893
ABSTRACT
The heterogeneity inherent in cancer means that even a successful clinical trial merely results in a therapeutic regimen that achieves, on average, a positive result only in a subset of patients. The only way to optimize an intervention for an individual patient is to reframe their treatment as their own, personalized trial. Toward this goal, we formulate a computational framework for performing personalized trials that rely on four mathematical techniques. First, mathematical models that can be calibrated with patient-specific data to make accurate predictions of response. Second, digital twins built on these models capable of simulating the effects of interventions. Third, optimal control theory applied to the digital twins to optimize outcomes. Fourth, data assimilation to continually update and refine predictions in response to therapeutic interventions. In this perspective, we describe each of these techniques, quantify their "state of readiness", and identify use cases for personalized clinical trials.
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: IScience Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: IScience Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos